scholarly journals Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome

Radiology ◽  
2016 ◽  
Vol 280 (3) ◽  
pp. 905-915 ◽  
Author(s):  
Maryam Aghighi ◽  
Justin Boe ◽  
Jarrett Rosenberg ◽  
Rie Von Eyben ◽  
Rakhee S. Gawande ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Ewing Sarcoma ◽  
Three Dimensional ◽  
Chemotherapy Response ◽  
Radiologic Assessment

Cytogenetic aberrations in Ewing sarcoma: Are secondary changes associated with clinical outcome?

1999 ◽  
Vol 32 (2) ◽  
pp. 79-83 ◽  
Author(s):  
Carl-Magnus Kullendorff ◽  
Fredrik Mertens ◽  
Mikael Donn�r ◽  
Thomas Wiebe ◽  
M�us �kerman ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Ewing Sarcoma ◽  
Cytogenetic Aberrations

Association of genomically unstable Ewing sarcoma tumors with HOTAIR overexpression and clinical outcome.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11035-11035
Author(s):  
Jamie D. Gardiner ◽  
Xiaomeng Huang ◽  
Evangelia Lazaris ◽  
Kevin Jones ◽  
Jeffrey T. Yap ◽  
...  
Keyword(s):  
Gene Expression ◽  
Clinical Outcome ◽  
Ewing Sarcoma ◽  
Copy Number ◽  
Bone Cancer ◽  
Cancer Cell Line ◽  
Chromosome 1Q ◽  
Non Coding Rna ◽  
Methylation Patterns ◽  
Microarray Analyses

11035 Background: Ewing sarcoma (ES) is the second most common bone cancer in children, characterized by the EWS-FLI1 fusion protein. Like most translocation-driven pediatric cancers, ES is a genomically “quiet” cancer with a low mutational burden and strong epigenetic regulation. However, recurring copy number alterations (CNAs) still arise in some ES tumors (e.g., chromosome 1q gain, 8 gain, 12 gain, and 16q loss) while other ES tumors completely lack genomic CNAs. We hypothesized that clinical, molecular, and epigenetic differences exist between these two unstable vs. stable genomic subtypes of ES. Methods: We performed CNA analysis on over 200 ES FFPE tumors. 30% of ES tumors had stable genomes while 60% had one or more CNAs across the genome. We performed gene expression and methylation microarray analyses on 24 ES FFPE tumors (11 stable, 13 unstable). Expression and methylation signatures were compared between stable vs. unstable ES and combined with clinical outcome. Results: Patients with unstable vs. stable ES tumors revealed worse 5-year overall (OS) and event-free survival (EFS) (38% vs. 67% EFS, p = 0.005; 58% vs. 84% OS, p = 0.0016). The subtypes had distinct expression and methylation signatures and clustered by methylation patterns. We identified differentially expressed and methylated genes, including upregulation (p = 0.0005) and unmethylation (p = 0.0009) of the long non-coding RNA HOTAIR in unstable vs. stable ES tumors. HOTAIR expression is higher in metastatic ES tumors compared to primary ES tumors (p = 0.02). Per the Cancer Cell Line Encyclopedia (Broad), ES cell lines have increased HOTAIR expression compared to 36 other cancers. Conclusions: ES genomic profiling through copy number, gene expression, and methylation identified at least two subtypes of ES (stable and unstable) that differ in outcome, gene expression and methylation. This data suggests HOTAIR’s involvement in ES pathogenesis, particularly in unstable tumors that have worse prognosis. Investigation is ongoing for HOTAIR expression as a prognostic and therapeutic target for ES, including a marker for LSD-inhibitor response.

scholarly journals NOVEL THREE DIMENSIONAL ECHOCARDIOGRAPHIC GUIDED OPTIMIZATION IMPROVES CLINICAL OUTCOME IN CARDIC RESYNCHRONIZATION THERAPY

2012 ◽  
Vol 59 (13) ◽  
pp. E1111
Author(s):  
Carolin Sonne ◽  
Lorenz Bott-Fluegel ◽  
Simon Hauck ◽  
Martin Hadamitzky ◽  
Hasema Lesevic ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Three Dimensional ◽  
Resynchronization Therapy

Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome

2011 ◽  
Vol 58 (4) ◽  
pp. 532-538 ◽  
Author(s):  
Jaume Mora ◽  
Eva Rodríguez ◽  
Carmen de Torres ◽  
Teresa Cardesa ◽  
José Ríos ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Signaling Pathway ◽  
Ewing Sarcoma ◽  
Pathway Expression

Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided cisplatin-based two-drug chemotherapy in unresectable non-small cell lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7118-7118
Author(s):  
Y. W. Moon ◽  
Y. T. Kim ◽  
J. H. Sohn ◽  
J. Chang ◽  
S. K. Kim ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Clinical Response ◽  
Response Rate ◽  
Predictive Accuracy ◽  
Clinical Response Rate ◽  
Chemotherapy Response ◽  
Chemosensitivity Test ◽  
Predictive Values ◽  
Platinum Sensitive ◽  
Response To Chemotherapy

7118 Background: Heterogeneity of tumor response to chemotherapy is a big obstacle in cancer treatment. The aim of this study was to investigate correlations of ATP-CRA and clinical outcome after ATP-TCA-guided cisplatin-based chemotherapy in unresectable NSCLC. Methods: From Sep. 2003 to Oct. 2005, ATP-CRA was done in tumor tissue specimen obtained from patients with suspected lung malignancy. ATP-CRA tested sensitivities of anticancer drugs used widely in advanced NSCLC such as cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabin, and vinorelbine. The cell death rate was determined by measuring the intracellular ATP levels of untreated controls and drug exposed cells. A sensitive drug was defined as a drug producing 30% or more reduction of ATP compared to untreated controls. Test-guided cisplatin-based two-drug chemotherapy was given to pathologically confirmed NSCLC. Results: 31 patients were enrolled and their median follow-up duration was 13.3 months. Response rate was 48.3%. Median progression-free and overall survivals were 4.4 months and 11.2 months, respectively. Patients were dichotomized into platinum-sensitive (S) and resistant (R) groups. S-group (19) contained cases sensitive to platinum alone (6) or both drugs (13). R-group (12) contained cases sensitive to none (9) or the other drug alone (3). Clinical response rate was higher in S-group (75.0% vs 35.3% in R-group; p = 0.0635). Considering correlations of test results and clinical response, positive/negative predictive values were 64.7% / 75.0% with the predictive accuracy of 69.0%. Although without significant differences in histology, stage, and performance status, S-group had longer progression-free (5.0 vs 2.4 months in R-group; p = 0.056) and overall (21.8 vs 9.7 months in R-group; p = 0.018) survivals. Conclusions: In vitro chemosensitivity test, ATP-CRA results and clinical outcome were correlated well after test-guided cisplatin-based two-drug chemotherapy in unresectable NSCLC, presenting favorable response and survival in platinum-sensitive versus resistant group. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document